In anticipation of a series of significant state elections, India is preparing for its second currency note exchange programme within a span of fewer than seven years. This time, the focus is on withdrawing the 2,000 rupees note from circulation.
Unlike the disruptive 2016 demonetisation move, which abruptly invalidated 86% of the country's currency overnight and resulted in a severe economic slowdown, the withdrawal of the highest denomination note is expected to cause far lesser disruption to the economy.
"The impact on the economy will be very marginal," said Reserve Bank of India Governor Shaktikanta Das at a briefing on Monday (22). The 2000-rupee notes were not commonly used in any transactions, he said.
Also, according to sources, the 2000-rupee notes were rarely utilised in daily transactions.
As the currency note exchange programme is set to commence on Tuesday (23), there has been an increase in gold purchases as individuals seek alternative stores of value to replace the soon-to-be obsolete 2000 rupee note.
Moreover, banks are preparing for an influx of customers depositing these notes, as reported by multiple sources.
In anticipation of upcoming elections in various Indian states, such as Rajasthan, Madhya Pradesh, Chhattisgarh, and Telangana, as well as the general election scheduled for next year, the withdrawal of the note has been initiated.
It is common for cash usage to increase during the election period, as candidates often employ cash transactions to get around the spending limits set by India's Election Commission.
In a notable occurrence, gold traded at a premium in India on Monday (22), breaking an 11-week trend. Some individuals, holding 2,000-rupee notes, chose to invest in the yellow metal instead of depositing their funds in banks.
However, Ashok Jain, proprietor of Mumbai-based gold wholesaler Chenaji Narsingji noted that there was a significant absence of a gold-buying frenzy reminiscent of the 2016 demonetisation period.
Additionally, bankers foresee reduced pressure compared to 2016 demonetisation, with September 30 deadline for retiring 2,000-rupee notes.
India's largest lender State Bank of India will increase cash counters for senior citizens and disabled persons so that any "rush, panic and inconvenience is avoided", said a top official.
According to the official, the bank plans to utilise mobile vans and engage business partners to facilitate the collection of such notes.
The official preferred to remain anonymous as he was not authorised to provide statements to the media. Additionally, three other banks have confirmed implementing similar measures.
"We do not expect a rush at banks to exchange the notes," central bank chief Das said. "People don't have to go immediately as enough time has been given."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.